Which is the main manufacturer of Upatinib/Ruifu?

Upadacitinib (Upadacitinib), trade name Rinvoq, is an oral Janus kinase (JAK) inhibitor that is widely used to treat various diseases related to the immune system, such asRheumatoid arthritis (RA), active psoriatic arthritis (PA), atopic dermatitis (AD), ulcerative colitis (UC), etc. The drug is developed and produced by the American pharmaceutical company AbbVie, which is responsible for its global promotion and sales. AbbVie has extensive research and product lines in the fields of immunology and oncology, and its advanced technologies in clinical research, drug development and production have made upadatinib a treatment option for many patients.

AbbVie Deutschland GmbH & Co. KG, a subsidiary of AbbVie, is responsible for the production of Ruifu. This company is located in Germany and is AbbVie's main production and R&D base in Europe. The company's production facilities comply with international pharmaceutical production quality standards and have advanced technical equipment to ensure the quality and safety of pharmaceutical production.

In addition to the original drug, there are also some generic versions of upadatinib on the market, which are usually produced by different pharmaceutical companies. A typical example is the generic drug produced by Lupine Pharmaceuticals in Laos. The ingredients of this drug are basically the same as the original drug Upatinib, and it is mainly used to treat the same indications as the original drug. The launch of generic drugs provides patients with a more economical choice, especially in some countries with lower economic levels. The price of generic drugs is often cheaper than the original drugs, which can help more patients get the treatment they need.

Although generic drugs contain the same ingredients as the brand-name drug, the manufacturing process, quality control, and bioequivalence may differ. When choosing generic drugs, patients should ensure that the drugs come from reputable manufacturers and consult their doctors for advice on the use of the drugs to ensure the effectiveness and safety of the treatment.

Reference materials:https://go.drugbank.com/drugs/DB15091